Cargando…

Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy

We describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy. She tolerated 13 cycles of chemotherapy without any significant hematological side effects, but after the 14th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tam, Eric L., Draksharam, Padma L., Park, Jennifer A., Sidhu, Gurinder S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875012/ https://www.ncbi.nlm.nih.gov/pubmed/31781443 http://dx.doi.org/10.1155/2019/4314797

Ejemplares similares

Findings of Multiple Myeloma in Afro-Caribbean Patients in the United States
por: Banavali, Ashtami, et al.
Publicado: (2018)

Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia
por: Pan, Elizabeth, et al.
Publicado: (2018)

A case of oxaliplatin-induced immune-mediated thrombocytopenia
por: Suh, Seong Eun, et al.
Publicado: (2014)

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
por: Woo, Hyun Sun, et al.
Publicado: (2015)

Antiplatelet antibodies in oxaliplatin-induced immune thrombocytopenia
por: Mittal, Kriti, et al.
Publicado: (2014)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature
por: Bautista, Marnelli A, et al.
Publicado: (2010)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma
por: Granda, T G, et al.
Publicado: (2002)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Alliot, C, et al.
Publicado: (2004)

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
por: Kawai, Sadayuki, et al.
Publicado: (2021)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Oxaliplatin but Not Irinotecan Impairs Posthepatectomy Liver Regeneration in a Murine Model
por: Soriano, Perry A., et al.
Publicado: (2011)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
por: Imai, Hiroo, et al.
Publicado: (2020)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Refractory Renal Cell Cancer with Gastro-renal Fistula: A Rare Complication
por: Tam, Eric, et al.
Publicado: (2020)

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
por: Tsujino, Takuya, et al.
Publicado: (2017)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
por: Sheikh, H Y, et al.
Publicado: (2008)

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001)

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer
por: Takahashi, Shin, et al.
Publicado: (2021)

Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
por: Zhang, Hangyu, et al.
Publicado: (2023)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
por: Lin, Xue, et al.
Publicado: (2015)

Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy
por: Chandar, Manisha, et al.
Publicado: (2015)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Effect of livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen
por: Emami, Hamid, et al.
Publicado: (2018)

Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients
por: Qingwei, Zhao, et al.
Publicado: (2020)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells
por: Frerker, Bernd, et al.
Publicado: (2023)

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
por: Zarate, R, et al.
Publicado: (2010)

A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2021)

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
por: Vasile, E, et al.
Publicado: (2009)

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2005)

Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
por: Sheikh, H Y, et al.
Publicado: (2007)

Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases
por: Liu, Jin-Hwang, et al.
Publicado: (2010)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_1i7vov9b8u3bir5jjqc7gtih67